Trends in Immunotherapy

Case Report

A case of delayed initial response to combination ipilimumab and nivolumab in malignant pleural mesothelioma

Downloads

https://doi.org/10.24294/ti8705
Hewa, C. P., & Khan, Y. (2014). A case of delayed initial response to combination ipilimumab and nivolumab in malignant pleural mesothelioma. Trends in Immunotherapy, 8(2). https://doi.org/10.24294/ti8705
Volume 8 Issue 2 (2024)
Copyright (c) 2014 Chamodi Pillippu Hewa, Yasir Khan
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright

The authors shall retain the copyright of their work but allow the Publisher to publish, copy, distribute, and convey the work.

License

Trends in Immunotherapy (TI)  publishes accepted manuscripts under Creative Commons Attribution 4.0 International (CC BY 4.0). Authors who submit their papers for publication by TI agree to have the CC BY 4.0 license applied to their work, and that anyone is allowed to reuse the article or part of it free of charge for any purpose, including commercial use. As long as the author and original source are properly cited, anyone may copy, redistribute, reuse, and transform the content.

Authors

  • Chamodi Pillippu Hewa
    Royal Perth Hospital, Perth, WA 6000
  • Yasir Khan Department of Medical Oncology, St John of God Midland Hospital, Midland, WA 6056; Peel Health Campus, Mandurah, WA 6210; Curtin Medical School, Curtin University, WA 6102

Malignant pleural mesothelioma has a poor prognosis with limited therapeutic options Although numerous trials have shown that combination immunotherapy with nivolumab and ipilimumab is one of the first line treatments for patients with unresectable MPM, there is limited data on delayed responses over a long follow up period. We report a case of a delayed response 7 months after the cessation of immunotherapy in a patient who initially had progressive malignant pleural mesothelioma with metastases.

Keywords:

malignant pleural mesothelioma immune checkpoint inhibitor ipilimumab nivolumab delayed response immunotherapy rechallenge overall survival

References

  1. Munot MN, Utpat KV, Desai UD, et al. Malignant mesothelioma-Report of two cases with different presentations. Indian Journal of Occupational and Environmental Medicine. 2019; 23(2): 93. doi: 10.4103/ijoem.IJOEM_237_18
  2. Popat S, Baas P, Faivre-Finn C, et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Annals of Oncology. 2022; 33(2): 129-142. doi: 10.1016/j.annonc.2021.11.005
  3. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet. 2021; 397(10272): 375-86. doi: 10.1016/S0140-6736(20)32714-8
  4. Mankor JM, Disselhorst MJ, Poncin M, et al. Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials. EBioMedicine. 2020; 62.
  5. Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. The Lancet Oncology. 2019; 20(2): 239-53. doi: 10.1016/S1470-2045(18)30765-4
  6. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. Journal of Clinical Oncology. 1996; 14(3): 1007-1017. doi: 10.1200/jco.1996.14.3.1007
  7. Tao AS. Systemic treatment for unresectable malignant pleural mesothelioma. Available online: https://www.uptodate.com/contents/systemic-treatment-for-unresectable-malignant-pleural-mesothelioma?search=treatment%2Bof%2Bmalignant%2Bpleural%2Bmesothelioma&source=search_result&selectedTitle=1~42&usage_type=default&display_rank=1 (accessed on 8 August 2023).
  8. Perrino M, De Vincenzo F, Cordua N, et al. Immunotherapy with immune checkpoint inhibitors and predictive biomarkers in malignant mesothelioma: Work still in progress. Frontiers in Immunology. 2023; 14: 1121557. doi: 10.3389/fimmu.2023.1121557
  9. Lee CW, Murray N, Anderson H, et al. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer. 2009; 64(3):308-13.
  10. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III Study of Pemetrexed in Combination with Cisplatin Versus Cisplatin Alone in Patients with Malignant Pleural Mesothelioma. Journal of Clinical Oncology. 2023; 41(12): 2125-2133. doi: 10.1200/jco.22.02542
  11. Peters S, Scherpereel A, Cornelissen R, et al. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Annals of Oncology. 2022; 33(5): 488-499. doi: 10.1016/j.annonc.2022.01.074
  12. Jones RG, Karthik F, Dugar A, et al. Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes. American Journal of Case Reports. 2018; 19: 783-789. doi: 10.12659/ajcr.909584
  13. Fennell D, Ottensmeier C, Califano R, et al. PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial. Journal of Thoracic Oncology. 2021; 16(3): S62. doi: 10.1016/j.jtho.2021.01.323
  14. Quispel-Janssen J, van der Noort V, de Vries JF, et al. Programmed Death 1 Blockade with Nivolumab in Patients with Recurrent Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 2018; 13(10): 1569-1576. doi: 10.1016/j.jtho.2018.05.038
  15. Disselhorst MJ, Quispel-Janssen J, Lalezari F, et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. The Lancet Respiratory Medicine. 2019; 7(3): 260-70. doi: 10.1016/S2213-2600(18)30420-X
  16. Spatola C, Militello C, Tocco A, et al. Intensity-Modulated Radiotherapy for Relapsed Malignant Pleural Mesothelioma. Future Oncology. 2016; 12(sup23): 67-71. doi: 10.2217/fon-2016-0330
  17. Spatola C, Militello C, Tocco A, et al. Single-Institution Experience of Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma at University of Catania. Future Oncology. 2018; 14(sup6): 17-21. doi: 10.2217/fon-2017-0280
  18. Guan Y, Feng D, Yin B, et al. Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade. Therapeutic Advances in Medical Oncology. 2022; 14. doi: 10.1177/17588359221096877
  19. Bernard-Tessier A, Baldini C, Castanon E, et al. Patterns of progression in patients treated for immuno-oncology antibodies combination. Cancer Immunology, Immunotherapy. 2020; 70(1): 221-232. doi: 10.1007/s00262-020-02647-z
  20. Wong A, Vellayappan B, Cheng L, et al. Atypical Response Patterns in Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors—Navigating the Radiologic Potpourri. Cancers. 2021; 13(7): 1689. doi: 10.3390/cancers13071689